ORMP Quote, Financials, Valuation and Earnings

Lifeward Ltd. has a net margin of -382.1% compared to Oramed Pharmaceuticals, Inc.'s net margin of -51.17%. Oramed Pharmaceuticals, Inc.'s return on equity of 27.49% beat Lifeward Ltd.'s return on equity of -150.63%.

Oramed Pharmaceuticals, Inc. has a consensus price target of $3.25, signalling downside risk potential of -1.52%. On the other hand Lifeward Ltd. has an analysts' consensus of $7.25 which suggests that it could grow by 1265.09%. Given that Lifeward Ltd. has higher upside potential than Oramed Pharmaceuticals, Inc., analysts believe Lifeward Ltd. is more attractive than Oramed Pharmaceuticals, Inc..

Oramed Pharmaceuticals, Inc. has a beta of 1.342, which suggesting that the stock is 34.249% more volatile than S&P 500. In comparison Lifeward Ltd. has a beta of 0.161, suggesting its less volatile than the S&P 500 by 83.916%.

Oramed Pharmaceuticals, Inc. has a quarterly dividend of $0.25 per share corresponding to a yield of 7.58%. Lifeward Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Oramed Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Lifeward Ltd. pays out -- of its earnings as a dividend.

Oramed Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Lifeward Ltd. quarterly revenues of $6.2M. Oramed Pharmaceuticals, Inc.'s net income of $48.4M is higher than Lifeward Ltd.'s net income of -$3.2M. Notably, Oramed Pharmaceuticals, Inc.'s price-to-earnings ratio is 3.29x while Lifeward Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Oramed Pharmaceuticals, Inc. is 68.69x versus 0.25x for Lifeward Ltd.. Usually stocks with elevated PS ratios are considered overvalued.

Merck & Co., Inc. has a net margin of -382.1% compared to Oramed Pharmaceuticals, Inc.'s net margin of 18.06%. Oramed Pharmaceuticals, Inc.'s return on equity of 27.49% beat Merck & Co., Inc.'s return on equity of 39.63%.

Oramed Pharmaceuticals, Inc. has a consensus price target of $3.25, signalling downside risk potential of -1.52%. On the other hand Merck & Co., Inc. has an analysts' consensus of $124.88 which suggests that it could grow by 2.65%. Given that Merck & Co., Inc. has higher upside potential than Oramed Pharmaceuticals, Inc., analysts believe Merck & Co., Inc. is more attractive than Oramed Pharmaceuticals, Inc..

Oramed Pharmaceuticals, Inc. has a beta of 1.342, which suggesting that the stock is 34.249% more volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.280, suggesting its less volatile than the S&P 500 by 72.042%.

Oramed Pharmaceuticals, Inc. has a quarterly dividend of $0.25 per share corresponding to a yield of 7.58%. Merck & Co., Inc. offers a yield of 2.7% to investors and pays a quarterly dividend of $0.85 per share. Oramed Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 45.05% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Oramed Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Merck & Co., Inc. quarterly revenues of $16.4B. Oramed Pharmaceuticals, Inc.'s net income of $48.4M is lower than Merck & Co., Inc.'s net income of $3B. Notably, Oramed Pharmaceuticals, Inc.'s price-to-earnings ratio is 3.29x while Merck & Co., Inc.'s PE ratio is 16.72x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Oramed Pharmaceuticals, Inc. is 68.69x versus 4.69x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Moderna, Inc. has a net margin of -382.1% compared to Oramed Pharmaceuticals, Inc.'s net margin of -121.83%. Oramed Pharmaceuticals, Inc.'s return on equity of 27.49% beat Moderna, Inc.'s return on equity of -29.19%.

Oramed Pharmaceuticals, Inc. has a consensus price target of $3.25, signalling downside risk potential of -1.52%. On the other hand Moderna, Inc. has an analysts' consensus of $41.60 which suggests that it could fall by -10.73%. Given that Moderna, Inc. has more downside risk than Oramed Pharmaceuticals, Inc., analysts believe Oramed Pharmaceuticals, Inc. is more attractive than Moderna, Inc..

Oramed Pharmaceuticals, Inc. has a beta of 1.342, which suggesting that the stock is 34.249% more volatile than S&P 500. In comparison Moderna, Inc. has a beta of 1.318, suggesting its more volatile than the S&P 500 by 31.821%.

Oramed Pharmaceuticals, Inc. has a quarterly dividend of $0.25 per share corresponding to a yield of 7.58%. Moderna, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Oramed Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Moderna, Inc. pays out -- of its earnings as a dividend.

Oramed Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Moderna, Inc. quarterly revenues of $678M. Oramed Pharmaceuticals, Inc.'s net income of $48.4M is higher than Moderna, Inc.'s net income of -$826M. Notably, Oramed Pharmaceuticals, Inc.'s price-to-earnings ratio is 3.29x while Moderna, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Oramed Pharmaceuticals, Inc. is 68.69x versus 9.32x for Moderna, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Instil Bio, Inc. has a net margin of -382.1% compared to Oramed Pharmaceuticals, Inc.'s net margin of --. Oramed Pharmaceuticals, Inc.'s return on equity of 27.49% beat Instil Bio, Inc.'s return on equity of -50.54%.

Oramed Pharmaceuticals, Inc. has a consensus price target of $3.25, signalling downside risk potential of -1.52%. On the other hand Instil Bio, Inc. has an analysts' consensus of $29.00 which suggests that it could grow by 226.58%. Given that Instil Bio, Inc. has higher upside potential than Oramed Pharmaceuticals, Inc., analysts believe Instil Bio, Inc. is more attractive than Oramed Pharmaceuticals, Inc..

Oramed Pharmaceuticals, Inc. has a beta of 1.342, which suggesting that the stock is 34.249% more volatile than S&P 500. In comparison Instil Bio, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Oramed Pharmaceuticals, Inc. has a quarterly dividend of $0.25 per share corresponding to a yield of 7.58%. Instil Bio, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Oramed Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Instil Bio, Inc. pays out -- of its earnings as a dividend.

Oramed Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Instil Bio, Inc. quarterly revenues of --. Oramed Pharmaceuticals, Inc.'s net income of $48.4M is higher than Instil Bio, Inc.'s net income of -$13.6M. Notably, Oramed Pharmaceuticals, Inc.'s price-to-earnings ratio is 3.29x while Instil Bio, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Oramed Pharmaceuticals, Inc. is 68.69x versus -- for Instil Bio, Inc.. Usually stocks with elevated PS ratios are considered overvalued.